In the SURMOUNT-2 study, which involved 938 adults with obesity or overweight and T2D, tirzepatide showed significant weight loss effects of 13.4% and 15.7% for the 10 and 15 mg doses, respectively, with over 80% of participants experiencing at least a 5% weight loss [92]
No, BPC-157 is not approved by the MHRA for any medical use in the UK, including erectile dysfunction
Get Started Disclaimer: No Medical Advice The information provided herein is for informational and educational purposes only and is not intended as, nor should it be construed as, medical advice, diagnosis, or treatment
For example, newer incretin therapies have demonstrated greater efficacy in weight reduction compared to earlier GLP-1 products during late-stage clinical trials
Race, gender, body size, disability, and financial status all shape their relationship to food and health
Once in use, the pen may be kept at room temperature (below 25C) for up to 30 days